šŸŽ Black Friday: 50% off Unlimited and 30% off Pro annual plans
Rapport Therapeutics, Inc. (RAPP)
NASDAQ: RAPP Ā· Real-Time Price Ā· USD
23.16
-0.43 (-1.82%)
At close: Nov 20, 2026, 4:00 PM EST
23.16
0.00 (0.00%)
After-hours: Nov 20, 2026, 7:30 PM EST
← View all transcripts

Jefferies Global Healthcare Conference

Nov 16, 2026

Summary

RAP-219 showed seizure reductions of 71% electrographically and 78% clinically, plus positive Phase II bipolar mania results. Phase III programs and a monthly injectable are advancing, with cash runway through 2029.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Okay, we're going to get started with our next session. I'm Andrew Tsai, senior biotech analyst at Jefferies, and thank you for joining me today. We have the Rapport team with me. To my left is Abe Ceesay, the CEO. To my direct right is Troy Ignelzi, CFO, and to his right is Jeff Sevigny, CMO. To start, I think Abe will be sharing some prepared remarks. I'll let you take it away.

Abe Ceesay
CEO, Rapport Therapeutics

Great. Can I just ask how I advance slides?

Oh, here we go. There we go. The one that says next and back. Perfect. All right. Well, good afternoon, everyone, and I want to just start by thanking Andrew and the rest of the Jefferies team for this opportunity. My name is Abe Ceesay. I'm the CEO here at Rapport Therapeutics. As a reminder, I will be making forward-looking statements throughout the presentation. Rapport is a company that was started through a collaboration between Third Rock and J&J to build a precision neuroscience company. We believe that precision really can come to life based on the scientific foundation of our company, which are receptor-associated proteins. The best way to think about receptor-associated proteins is through our lead program, which is a TARPγ8 AMPA modulator. I'll spend much more time on the novelty of this program as well as the indications that we're pursuing.

We launched Rapport and really thought about RAP-219 from the outset as a pipeline and a product opportunity. In 2025, we achieved proof of concept results with RAP-219 in focal onset seizures with truly unprecedented efficacy. Most recently, in 2026, we also achieved proof of concept with RAP-219 in bipolar mania. We're a well-capitalized company based on our recent financing on the backs of the bipolar data with roughly $814 million. Here's a quick snapshot of our pipeline. First, just looking at RAP-219 and orienting you to that pipeline and a product vision. We're currently enrolling our phase III studies in focal onset seizures, referred to as FOCUS 1 and FOCUS 2. We're also looking to initiate our phase III program in primary generalized tonic-clonic seizures, which is the next largest form of adult epilepsy.

Finally, as I spoke to on the previous slide, moving our bipolar mania trial into phase III. To round all of this out, we are developing a long-acting injectable formulation for RAP-219. We believe that this would be transformational for all indications that we're currently pursuing with the asset. In addition to RAP-219, we have a fully integrated discovery effort that is leveraging receptor associated proteins. Our lead program there is a nicotinic program, α6β4, which we're looking to move into the clinic for phase I in 2027. As you think about this pipeline and a product opportunity, it is one that is significant. As you look across the three populations, focal onset seizures, primary generalized tonic-clonic seizures, as well as bipolar mania, really represent multi-billion dollar market opportunities, primarily in focal onset seizures as well as bipolar mania.

As you think about the long-acting injectable, that has the opportunity to expand the clinical utility across all indications, but also really increase the terminal value of RAP-219 with the IP around the long-acting formulation being able to extend beyond the traditional composition of matter loss of exclusivity. So, let's take a moment to just reflect on the novelty and the potential for RAP-219 given the receptor associated protein science. TARPγ8, which is the receptor associated protein associated with the AMPA receptor, is primarily expressed in four brain structures, and you can see that reflected on the right-hand side in the PET receptor occupancy images. What's important about this is that concentration of TARPγ8 associated with AMPA receptors really overlays very nicely with what we understand around the disease biology in both focal onset seizures as well as bipolar mania.

Specifically for focal onset seizures start in the mesial temporal lobe as well as propagate in the mesial temporal lobe, as well as the cerebral cortex. In bipolar mania, what we understand about that disease is that disease is characterized by increased glutamate levels, and those glutamate levels are contained in a network, which is the cortico-limbic network, again, which overlays with the expression of TARPγ8. So, I first want to just review the data that we have seen with RAP-219 in focal onset seizures. We took an innovative approach to our proof of concept study. This proof of concept study specifically enrolled patients that were refractory focal onset seizure patients. That's the same type of patients that are ultimately enrolled in a phase III study. The innovative aspect of this study was that these patients had an implantable neurostimulation device known as the RNS device.

In terms of our trial, the stimulation or the treatment was not really important. What was important is that this device allows for constant EEG recording and allowed us to leverage a novel biomarker to make the study much more efficient, but also to corroborate the changes that we saw in clinical seizures. So, in terms of the results of that study, as I mentioned, these results were truly unprecedented in terms of efficacy that we observed with RAP-219. On the left-hand side, what you see is the primary endpoint, which is that electrographic endpoint or long episodes. You should consider these electrographic seizures. As you can see, we saw roughly a 71% reduction in electrographic seizures.

On the right-hand side, you can see how that corroborates the effects that we saw in clinical seizures, with a 78% reduction in clinical seizures, which is really unprecedented as you think about effects of anti-seizure medications. Importantly, on the far-hand right bar, what you see is a 24% seizure freedom rate. This is ultimately what is the goal of care for patients. A 24% seizure freedom rate, one, is not impacted by placebo. Overall, seizure freedom is not impacted by placebo, but the 24% of patients achieving seizure freedom is really one of the highest that has been observed with anti-seizure medications. From a tolerability standpoint, the drug was well tolerated. You can see that the most common AEs were dizziness, headache, and fatigue. All AEs were mild to moderate. Now moving to our bipolar data.

Before I go through the actual results of the bipolar data, I want to set the context for the bipolar patient. This is a patient population that has significant unmet need. These patients show up either in the inpatient or outpatient setting in a manic episode. They are treated acutely today with three main areas of treatment. One is atypical antipsychotics, two are the anti-seizure medications that are approved for bipolar, and then third is lithium. All of these current medications for these patients carry very burdensome AE profile, and ultimately what occurs is that unfortunately these patients have a very high discontinuation rate. Roughly 40% of patients discontinue, and then we are back in a cycle for these patients where they are ultimately cycling back to another manic episode.

The AEs that are most common with currently available therapies are all of the AEs that are well-known for atypical antipsychotics, sedation, akathisia, extrapyramidal symptoms, weight gain, metabolic changes, as an example, and all of these AEs are AEs that ultimately drive patients to stop taking their treatment. We believe that RAP-219 could be transformational for this patient population. The first aspect is that there has not been a novel mechanism in bipolar mania in over three decades. Presenting a novel mechanism of action for this patient population could be very important. Second, given the profile of RAP-219, one, it is not interrogating the dopaminergic channel, and two, it is approaching a different neurotransmitter in glutamate, we believe could be a really nice option both for clinicians as well as patients. We just completed, as I mentioned, our phase II proof of concept trial.

This was a standard trial in bipolar mania, one that was not innovative, such as our proof of concept study in epilepsy, a very standard approach. It was a large placebo-controlled randomized trial. It consisted of three weeks, or 21 days, of inpatient treatment, followed by an eight-week follow-up period. Just a quick snapshot of the patient disposition. You can see that 253 patients were randomized, 127 in the placebo arm, 126 in the RAP-219 arm. You can see the discontinuation of treatment. There were 31 patients in the RAP-219 arm compared to 15 patients in the placebo arm. You can see the main reason for discontinuation across both arms was withdrawal of consent, which is a common reason why patients withdraw in bipolar mania studies. You can see that there is an imbalance between RAP-219 as well as placebo. Importantly, this discontinuation was not driven by AEs.

When we understand and look further at this data and understand why patients were withdrawing from consent, our understanding is that patients that were on RAP-219 were either at baseline or actually improving, as compared to placebo patients that were either at baseline or worsening. You can see the overall withdrawal rate due to AEs was low, with 3.2% in the RAP-219 arm compared to 0.8% in the placebo arm. Looking at the primary endpoint, which is the YMRS, which is the standard endpoint for bipolar mania, we observed a 3.1 placebo-adjusted difference in the YMRS scale at week three. Importantly, as you look at these results, what you can see is a clear, consistent effect of the treatment arm. The lines never touch or never cross going across the treatment period.

What you can also observe is the absolute change in the treatment arm, RAP-219, of 15.4. This is a very meaningful change. Looking historically based on drug development in bipolar mania, 15.4 is in the top five absolute effects that you see in all other trials, in all other agents. Importantly, when you look at the YMRS, the YMRS contains 11 single items that make up the overall scale. When we look at these 11 items, all 11 items improved on drug. Importantly, four items met significance, and those are irritability, content, disruptive aggressive behavior, and as well as sexual interest. The top three, irritability, content, disruptive, and aggressive behavior are some of the most important measures of a manic episode and ultimately are the items that either drive hospitalization or keep patients hospitalized.

To see this meaningful effect with RAP-219, we think really confirms the pharmacology of the asset overall. Next is the secondary endpoint, which is the Clinical Global Impression Scale in bipolar mania. We also saw a statistically significant effect and treatment difference with RAP-219 compared to placebo of 0.4, which is right in line with what you have seen historically with other effective and approved products. Finally, just touching on tolerability, the drug was well tolerated in this patient population. All AEs were mild to moderate. The overall TEAEs observed in greater than 5% of patients were agitation, insomnia, restlessness, anxiety, headache, and nausea. Of these, nausea was the only TEAE that was reported in greater than two times patients on RAP-219 compared to placebo. The most common TEAE in the RAP-219 group was agitation. Importantly, these patients are agitated at baseline. It is part of their overall disease.

What we saw in this was that greater than 80% of patients who reported agitation, it was considered unrelated, and the mean duration of agitation was two days, and really self-resolved. As we think about moving this program into phase III, we are really confident with these results and that they will translate into phase III. Importantly, based on our learnings from phase II, we also believe we can enhance our phase III studies. We believe that there are some protocol changes that we can make. We can also move to a higher dose, which I will touch on in a moment, as well as expanding the geography of the trial as well. What is well understood is that the U.S. also drives high placebo rates, and we did see a higher-than-normal placebo rate in our trial.

By going to global sites, we believe that we can manage that placebo rate more effectively. In terms of dose, we did take the 0.75 dose into the bipolar trial, and that was the dose that was evaluated. This dose is a dose that gets to a meaningful point in terms of receptor occupancy. Our goal or objective for receptor occupancy is to be above 50% and ultimately achieve something between 70% to 80%. What you can see on that bottom line is the 0.75 dose, and by going to a 1.25 dose, we can not only increase the overall receptor occupancy, getting above 80%, but importantly, we can pull in those exposures that were achieved with a 0.75 dose at 21 days. We can pull in those exposures at day seven to 10, which we think could result into a clinically meaningful difference earlier in the trial.

Last, in terms of the overall target product profile is developing the long-acting injectable. A long-acting injectable has not been developed with an anti-seizure medication, and that's not based on the lack of need. That's based on the limitations of current anti-seizure medications. Many anti-seizure medications have very high doses. They have drug-drug interaction profiles. They inherently have a low half-life, so the ability to formulate them into a long-acting injectable isn't very feasible. When you look at RAP-219, it has some very unique characteristics. First, it is extremely potent drug. As I mentioned, we're talking about therapeutic doses of 0.75 to 1.25. We're also evaluating the 0.25 dose in our phase III studies. It has a low clearance and inherently long half-life in the oral formulation, roughly 22 days, and it has low solubility. That allows us to move forward with a long-acting injectable.

This could be transformational for epilepsy patients. The biggest concern for an epilepsy patient, their family, a clinician, is missing a dose. There's a risk of a breakthrough seizure that has very high morbidity as well as sometimes mortality. The ability to have a long-acting injectable could be highly differentiating for RAP-219, and based on our research, has the opportunity to double sales. Just looking at our catalysts moving forward, we feel like we have a robust outlook for the company. We're well-financed with roughly $814 million. That provides us runway through 2029 and allows us to complete our two phase III trials in FOS, as well as our two phase III trials in bipolar mania, as well as all of the milestones that are listed here on the slide.

Coming up in the fourth quarter, we're going to have our data from our open-label extension study in focal onset seizures. These are patients that were included and are involved in our phase II proof of concept study. They had the opportunity to go into an open-label extension study. Importantly, these patients did not roll directly into an open-label extension study, so there was a break where these patients were off therapy but then had the opportunity to roll into this long-term safety study. We believe that this could be really informative as we think about the long-term profile of the drug. In the first quarter, we're planning to have an FDA meeting around our bipolar program, and that would be our End-of-Phase II meeting that would be informative of ultimately starting the bipolar program in the second half, and those would be two parallel phase III studies.

In the first half of 2027, we also anticipate that we will launch the primary generalized tonic-clonic seizure phase III program. In the third quarter, we are going to have our initial data for PK for the long-acting injectable formulation as well. We also will be moving our pipeline product, RAP-641. This is our α6β4 nicotinic program focused on both migraine as well as neuropathic pain, and we will have the phase I results in the second half of 2027. With that, we will turn it over to Andrew for some Q&A and thank you for the time.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Yeah, no problem. In the last five minutes, maybe starting with the bipolar program, I noticed you guys didn't necessarily say the phase II results were necessarily pivotal, but is that your understanding, meaning you are running two phase IIIs now, could one serve as a backup?

Abe Ceesay
CEO, Rapport Therapeutics

Jeff, you want to take that?

Jeff Sevigny
CMO, Rapport Therapeutics

Yeah, exactly. The idea is that we would run three studies to at least have two positives, ideally all three. The phase II study was designed with that intent in terms of the rigor of the study and the statistical analysis, specifically the alpha and the power.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Great. It sounds like one of the strategies to get more efficacy in the phase III is to push up a dose. Can you speak to that dose level? Is there a risk of more AEs popping up, for instance?

Jeff Sevigny
CMO, Rapport Therapeutics

Yeah. The protocol is not final yet, but the thinking is that we would go to probably 1.25 mg. The rationale was articulated by Abe. Essentially, we achieve higher ROs at an earlier time point and at the final week three time point. In terms of safety and tolerability, we feel like that's de-risked because we did test 1.25 mg in the phase II FOS study. Of course, in the healthy volunteer studies, 1.25 mg, frankly up to 1.75 mg, was well tolerated in multiple dose studies.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Just to be clear, with the phase II study, are these patients done? Is there an open-label extension, or is that going to be part of the phase III?

Jeff Sevigny
CMO, Rapport Therapeutics

In bipolar, there was not an open-label study for the phase II participants.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Okay.

Jeff Sevigny
CMO, Rapport Therapeutics

There will be for phase III, but not for phase II.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Makes sense. As for the phase III, how are you guys thinking about powering the study? Here, you show three-point separation, but maybe you think you can get more efficacy. Would you power for four, on placebo-adjusted on YMRS?

Jeff Sevigny
CMO, Rapport Therapeutics

In that ballpark, it would be 90% powered. Alpha would be set at 0.05. Powering, it would be in the four range.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Okay. I think one tweak is that the phase II was inpatient, phase III will be outpatient. Is that true? If so, does going outpatient affect placebo behavior, and how do you control for placebo?

Jeff Sevigny
CMO, Rapport Therapeutics

In bipolar?

Andrew Tsai
Senior Biotech Analyst, Jefferies

In bipolar.

Jeff Sevigny
CMO, Rapport Therapeutics

These are things we are still discussing for the protocol design. Historically, at least more recently, the phase III studies have allowed patients to leave with day passes, and they have allowed patients to be discharged early, typically after week two. That is because patients do not want to stay inpatient for the entire three-week period, and it leads to things like withdrawal of consent. One way to mitigate that is to permit them to leave under some strict guidance. Of course, they need to be stable, and there needs to be ways to monitor them.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Okay. Abe, you said earlier the cash runway that you have should last until you have completed all four epilepsy and bipolar studies. We can infer bipolar phase III data and epilepsy data by then?

Abe Ceesay
CEO, Rapport Therapeutics

Yes.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Okay. Meanwhile, back in epilepsy, you have a long-acting. Ultimately, what is that dosing frequency in the phase for this program that you want to achieve? Secondly, once you do report phase I data, what is positive data, and what is the next steps from there?

Abe Ceesay
CEO, Rapport Therapeutics

Yeah. So, our initial target product profile for the long-acting injectable formulation is 30 days. In terms of the phase I data that we will have next year, really the goal is to ensure that the target product profile is met in terms of PK. So, what we want to see is we don't want to see any dose dumping or significant fluctuations in exposure. Based on that, we would move forward with additional studies. I will say that as you look at long-acting injectable development, this is the most important de-risking phase. If you can achieve a steady profile, a profile that ultimately meets your PK characteristics, that is the largest de-risking time point. Based on all of the work that our teams have done, we feel confident going into this study.

Andrew Tsai
Senior Biotech Analyst, Jefferies

Last question. That phase III epilepsy program, like you said, phase II was 78% absolute seizure reduction. How have you powered the phase III drug versus placebo?

Abe Ceesay
CEO, Rapport Therapeutics

Jeff?

Jeff Sevigny
CMO, Rapport Therapeutics

Yeah, much more conservatively, in line with what other more recently conducted phase III programs have powered their phase III studies. Some are in the 30%-35% placebo-adjusted reduction in seizure frequency. So, if we achieve anything near what we saw in phase II, the studies are way overpowered.

Andrew Tsai
Senior Biotech Analyst, Jefferies

All right. I think that's all the time we have. Thank you, all of you, for joining, and thanks everyone for listening.

Abe Ceesay
CEO, Rapport Therapeutics

Thanks, Andrew.